Every material Form 8-K ACTUATE THERAPEUTICS, INC. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Actuate Therapeutics received a Nasdaq notice on October 28, 2026, stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027 to regain compliance, and the stock continues to trade on The Nasdaq Global Market as ACTU for now. If it does not regain compliance, the stock could become subject to delisting, which matters to shareholders.
Nasdaq notice received October 28, 2026 under Listing Rule 5450(a)(1)
Compliance deadline is April 26, 2027; stock must close at or above $1.00 for at least 10 consecutive business days
Separate July 15, 2026 notice on minimum market value of listed securities; regain compliance by January 11, 2027
A second 180-day period may be available if the company moves its listing to the Nasdaq Capital Market
Actuate Therapeutics closed an underwritten public offering on October 28, 2026, selling 30,985,900 shares of common stock and warrants for up to 15,492,950 shares, with Newbridge Securities Corporation as sole book-running manager. Net proceeds were approximately $9.96 million, which the company intends to use for working capital and general corporate purposes. The new shares and warrants increase the number of shares outstanding and could dilute existing shareholders.
Offering priced at $0.71 per set of two shares and one Common Warrant, before underwriting discounts and commissions
Common Warrants exercisable at $0.45 per share, immediately upon issuance, expiring five years after issuance
Net proceeds of approximately $9.96 million; the press release had projected gross proceeds of $11.0 million
Underwriter has a 45-day option to buy up to 4,647,885 additional shares and 2,323,942 additional warrant shares
Actuate Therapeutics received a Nasdaq notice that its Market Value of Listed Securities fell below the $50 million minimum for continued listing on the Nasdaq Global Market from June 1, 2026 to July 14, 2026. The common stock continues to trade under the symbol ACTU, and the company has until January 11, 2027 to regain compliance, which could lead to delisting proceedings if it does not.
Nasdaq notice dated July 15, 2026 cites a market value of listed securities below the $50 million minimum for the period June 1, 2026 to July 14, 2026.
The common stock continues to trade on the Nasdaq Global Market under ACTU, as the notice has no immediate effect on listing.
Compliance Date is January 11, 2027; regaining compliance requires closing at $50 million or more for at least ten consecutive business days.
If compliance is not regained, Nasdaq will issue a delisting notice, which the company may appeal, or the company may consider transfer to the Nasdaq Capital Market.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ACTUATE THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →